Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations

References

• Arnold, K., Bordoli, L., Kopp, J., & Schwede, T. (2006). The SWISS-MODEL workspace: A web-based environment for protein structure homology modelling. Bioinformatics, 22, 195–201. doi: 10.1093/bioinformatics/bti770
   PubMed Web of Science ®Google Scholar
• Awad, M. M., Katayama, R., McTigue, M., Liu, W., Deng, Y. L., Brooun, A., … Shaw, A. T. (2013). Acquired resistance to crizotinib from a mutation in CD74 – ROS1. New England Journal of Medicine, 368, 2395–2401. doi:10.1056/NEJMc1309091
   PubMed Web of Science ®Google Scholar
• Bayly, C. I., Cieplak, P., Cornell, W., & Kollman, P. A. (1993). A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: The RESP model. The Journal of Physical Chemistry, 97, 10269–10280. doi:10.1021/j100142a004
   Web of Science ®Google Scholar
• Bergethon, K., Shaw, A. T., Ignatius Ou, S. H., Katayama, R., Lovly, C. M., McDonald, N. T., … Iafrate, A. J. (2012). ROS1 rearrangements define a unique molecular class of lung cancers. Journal of Clinical Oncology, 30, 863–870. doi:10.1200/JCO.2011.35.6345
   PubMed Web of Science ®Google Scholar
• Bubendorf, L., Büttner, R., Al-Dayel, F., Dietel, M., Elmberger, G., Kerr, K., … Thunnissen, E. (2016). Testing for ROS1 in non-small cell lung cancer: A review with recommendations. Virchows Archiv, 469, 489–503. doi:10.1007/s00428-016-2000-3
   PubMed Web of Science ®Google Scholar
• Case, D., Darden, T., Cheatham, T., III, Simmerling, C., Wang, J., Duke, R., … Kollman, P. (2012). AMBER 12. San Francisco: University of California.
   Google Scholar
• Cui, J. J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P., Pairish, M., … Edwards, M. P. (2011). Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). Journal of Medicinal Chemistry, 54, 6342–6363. doi:10.1021/jm2007613
   PubMed Web of Science ®Google Scholar
• Darden, T., York, D., & Pedersen, L. (1993). Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. The Journal of Chemical Physics, 98, 10089–10092.10.1063/1.464397
   Web of Science ®Google Scholar
• Davare, M. A., Vellore, N. A., Wagner, J. P., Eide, C. A., Goodman, J. R., Drilon, A., … Druker, B. J. (2015). Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proceedings of the National Academy of Sciences, 112, E5381–E5390. doi:10.1073/pnas.1515281112
   PubMed Web of Science ®Google Scholar
• Frisch, M., Trucks, G., Schlegel, H., Scuseria, G., Robb, M., Cheeseman, J., … Burant, J. (2004). Gaussian 03. Wallingford, CT: Gaussian.
   Google Scholar
• Götz, A. W., Williamson, M. J., Xu, D., Poole, D., Le Grand, S., & Walker, R. C. (2012). Routine microsecond molecular dynamics simulations with AMBER on GPUs. 1. Generalized born. Journal of Chemical Theory and Computation, 8, 1542–1555. doi:10.1021/ct200909j
   PubMed Web of Science ®Google Scholar
• Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., & Simmerling, C. (2006). Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins: Structure, Function, and Bioinformatics, 65, 712–725. doi:10.1002/prot.21123
   PubMed Web of Science ®Google Scholar
• Hou, T., Wang, J., Li, Y., & Wang, W. (2011). Assessing the performance of the MM/PBSA and MM/GBSA Methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. Journal of Chemical Information and Modeling, 51, 69–82. doi:10.1021/ci100275a
   PubMed Web of Science ®Google Scholar
• Hou, J., Wan, S., Wang, G., Zhang, T., Li, Z., Tian, Y., … Zhang, J. (2016). Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3- d]pyrimidine derivatives targeting epidermal growth factor receptor. European Journal of Medicinal Chemistry, 118, 276–289. doi:10.1016/j.ejmech.2016.04.026
   PubMed Web of Science ®Google Scholar
• Johnson, T. W., Richardson, P. F., Bailey, S., Brooun, A., Burke, B. J., Collins, M. R., … Edwards, M. P. (2014). Discovery of (10R)-7-amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno)pyrazolo[4, 3-h][2, 5, 11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. Journal of Medicinal Chemistry, 57, 4720–4744. doi:10.1021/jm500261q
   PubMed Web of Science ®Google Scholar
• Kazandjian, D., Blumenthal, G. M., Luo, L., He, K., Fran, I., Lemery, S., & Pazdur, R. (2016). Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell lung cancer. The Oncologist, 21, 974–980. doi:10.1634/theoncologist.2016-0101
   PubMed Web of Science ®Google Scholar
• Onufriev, A., Bashford, D., & Case, D. A. (2004). Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins: Structure, Function, and Bioinformatics, 55, 383–394. doi:10.1002/prot.20033
   PubMed Web of Science ®Google Scholar
• Ou, S. H., Tan, J., Yen, Y., & Soo, R. A. (2012). ROS1 as a ‘druggable’ receptor tyrosine kinase: Lessons learned from inhibiting the ALK pathway. Expert Review of Anticancer Therapy, 12, 447–456. doi:10.1586/era.12.17
   PubMed Web of Science ®Google Scholar
• Pathak, D., Chadha, N., & Silakari, O. (2016). Identification of non-resistant ROS-1 inhibitors using structure based pharmacophore analysis. Journal of Molecular Graphics and Modelling, 70, 85–93. doi:10.1016/j.jmgm.2016.09.013
   PubMed Web of Science ®Google Scholar
• Rocchia, W., Alexov, E., & Honig, B. (2001). Extending the applicability of the nonlinear Poisson−Boltzmann equation: Multiple dielectric constants and multivalent ions. The Journal of Physical Chemistry B, 105, 6507–6514.10.1021/jp010454y
   Web of Science ®Google Scholar
• Ryckaert, J., Ciccotti, G., & Berendsen, H. (1977). Numerical integration of the Cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. Journal of Computational Physics, 23, 327–341.10.1016/0021-9991(77)90098-5
   Web of Science ®Google Scholar
• Salomon-Ferrer, R., Götz, A. W., Poole, D., Le Grand, S., & Walker, R. C. (2013). Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh Ewald. Journal of Chemical Theory and Computation, 9, 3878–3888. doi:10.1021/ct400314y
   PubMed Web of Science ®Google Scholar
• Sun, H., Li, Y., Tian, S., Wang, J., & Hou, T. (2014). P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: Clues from free energy landscape. PLoS Computational Biology, 10, e1003729. doi:10.1371/journal.pcbi.1003729
   PubMed Web of Science ®Google Scholar
• Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004). Development and testing of a general amber force field. Journal of Computational Chemistry, 25, 1157–1174. doi:10.1002/jcc.20035
   PubMed Web of Science ®Google Scholar
• Weiser, J., Shenkin, P. S., & Still, W. C. (1999). Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO). Journal of Computational Chemistry, 20, 217–230. doi:10.1002/(SICI)1096-987X(19990130)20:2<217::AID-JCC4>3.0.CO;2-A
   Web of Science ®Google Scholar
• Wu, X., Fu, Y., Wang, Y., Wan, S., & Zhang, J. (2017a). Computational investigation on inhibition mechanism of BRAFV600E by Vemurafenib (PLX4032) and its analogue PLX4720. Medicinal Chemistry Research, 26, 390–396. doi:10.1007/s00044-016-1757-x
   Web of Science ®Google Scholar
• Wu, X., Fu, Y., Wang, Y., Wan, S., & Zhang, J. (2017b). Gaining insight into crizotinib resistance mechanisms caused by L2026 M and G2032R mutations in ROS1 via molecular dynamics simulations and free-energy calculations. Journal of Molecular Modeling, 23, 447–447146. doi:10.1007/s00894-017-3314-z
   Web of Science ®Google Scholar
• Wu, X., Wan, S., Wang, G., Jin, H., Li, Z., Tian, Y., … Zhang, J. (2015). Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2. Journal of Molecular Graphics and Modelling, 56, 103–112. doi:10.1016/j.jmgm.2014.12.006
   PubMed Web of Science ®Google Scholar
• Zou, H. Y., Li, Q., Engstrom, L. D., West, M., Appleman, V., Wong, K. A., … Fantin, V. R. (2015). PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proceedings of the National Academy of Sciences, 112, 3493–3498. doi:10.1073/pnas.1420785112
   PubMed Web of Science ®Google Scholar